[go: up one dir, main page]

MX2010000315A - Un medicamento inhalable. - Google Patents

Un medicamento inhalable.

Info

Publication number
MX2010000315A
MX2010000315A MX2010000315A MX2010000315A MX2010000315A MX 2010000315 A MX2010000315 A MX 2010000315A MX 2010000315 A MX2010000315 A MX 2010000315A MX 2010000315 A MX2010000315 A MX 2010000315A MX 2010000315 A MX2010000315 A MX 2010000315A
Authority
MX
Mexico
Prior art keywords
solid
inhalable medicament
tiotropium bromide
sugar
pharmaceutically acceptable
Prior art date
Application number
MX2010000315A
Other languages
English (en)
Inventor
Xian-Ming Zeng
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38566522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010000315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of MX2010000315A publication Critical patent/MX2010000315A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a un medicamento inhalable y en particular a una forma nueva en estado sólido de bromuro de tiotropio, a saber partículas amorfas sólidas que comprenden una mezcla intima de bromuro de tiotropio junto con un co-sólido farmacéuticamente aceptable teniendo una temperatura de transición vítrea de por lo menos -50°C, tal como un azúcar y/o un derivado de azúcar.
MX2010000315A 2007-07-09 2008-07-03 Un medicamento inhalable. MX2010000315A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95882307P 2007-07-09 2007-07-09
GBGB0716026.0A GB0716026D0 (en) 2007-08-16 2007-08-16 An inhalable medicament
PCT/GB2008/002294 WO2009007687A2 (en) 2007-07-09 2008-07-03 An inhalable medicament

Publications (1)

Publication Number Publication Date
MX2010000315A true MX2010000315A (es) 2010-03-17

Family

ID=38566522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000315A MX2010000315A (es) 2007-07-09 2008-07-03 Un medicamento inhalable.

Country Status (20)

Country Link
US (3) US8759369B2 (es)
EP (1) EP2175838B2 (es)
JP (1) JP5552049B2 (es)
KR (1) KR101542632B1 (es)
CN (1) CN101754749B (es)
BR (1) BRPI0813564A2 (es)
CA (1) CA2692606C (es)
CY (1) CY1115937T1 (es)
DK (1) DK2175838T4 (es)
EA (2) EA030829B1 (es)
ES (1) ES2526647T5 (es)
GB (1) GB0716026D0 (es)
HR (1) HRP20141175T4 (es)
IL (2) IL203180A (es)
MX (1) MX2010000315A (es)
PL (1) PL2175838T5 (es)
PT (1) PT2175838E (es)
RS (1) RS53784B2 (es)
SI (1) SI2175838T2 (es)
WO (1) WO2009007687A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
PT2230934E (pt) 2007-12-14 2012-11-20 Aerodesigns Inc Distribuir produtos alimentares aerossolizáveis
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
CN103110584A (zh) * 2013-01-29 2013-05-22 青岛大学 一种噻托溴铵粉雾剂及其制备方法
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
EP2913332A1 (en) 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
GB201409603D0 (en) * 2014-05-30 2014-07-16 Teva Pharmaceuticals Europ B V An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR101728116B1 (ko) * 2015-11-03 2017-04-18 한미약품 주식회사 티오트로피움 또는 이의 약학적으로 허용가능한 염을 함유하는 흡입용 건조분말 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB9027234D0 (en) * 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
EP1238661A1 (en) 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
EP1326862B1 (de) 2000-10-12 2004-09-15 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DZ3477A1 (es) 2000-10-12 2002-04-18
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
WO2005027875A1 (en) * 2003-09-18 2005-03-31 Ivax Corporation Particles
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
JP4553902B2 (ja) 2003-11-03 2010-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用を有する新規結晶性無水物
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
CN1270709C (zh) * 2004-01-19 2006-08-23 复旦大学 一种噻托溴铵吸入粉雾剂及其制备方法
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CN1593414A (zh) * 2004-07-02 2005-03-16 上海华拓医药科技发展有限公司 一种噻托溴铵胶囊型吸入粉雾剂及其制备方法
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
CA2606552A1 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
AU2006259202B2 (en) 2005-06-15 2012-05-10 Boehringer Ingelheim International Gmbh Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
CA2627729A1 (en) * 2005-12-19 2007-07-05 Sicor Inc. Novel forms of tiotropium bromide and processes for preparation thereof
EP1923393A1 (en) * 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea

Also Published As

Publication number Publication date
PT2175838E (pt) 2015-01-14
DK2175838T4 (en) 2017-08-28
HRP20141175T1 (hr) 2015-03-13
ES2526647T3 (es) 2015-01-14
CA2692606A1 (en) 2009-01-15
CY1115937T1 (el) 2017-01-25
ES2526647T5 (es) 2017-10-10
IL236360A0 (en) 2015-09-24
WO2009007687A3 (en) 2009-06-04
EP2175838A2 (en) 2010-04-21
WO2009007687A2 (en) 2009-01-15
KR20100045999A (ko) 2010-05-04
KR101542632B1 (ko) 2015-08-06
EA201070115A1 (ru) 2010-06-30
BRPI0813564A2 (pt) 2015-08-25
IL203180A (en) 2015-01-29
US20100326437A1 (en) 2010-12-30
DK2175838T3 (en) 2015-01-05
PL2175838T5 (pl) 2018-03-30
EA201500111A1 (ru) 2015-10-30
US8759369B2 (en) 2014-06-24
JP5552049B2 (ja) 2014-07-16
RS53784B1 (sr) 2015-06-30
GB0716026D0 (en) 2007-09-26
EA030829B1 (ru) 2018-10-31
US20150150808A1 (en) 2015-06-04
RS53784B2 (sr) 2018-07-31
SI2175838T1 (sl) 2015-03-31
JP2010533156A (ja) 2010-10-21
CA2692606C (en) 2014-04-01
EP2175838B2 (en) 2017-06-07
EA020968B1 (ru) 2015-03-31
US20140127304A1 (en) 2014-05-08
EP2175838B1 (en) 2014-10-08
HRP20141175T4 (hr) 2017-09-22
CN101754749A (zh) 2010-06-23
CN101754749B (zh) 2016-04-13
SI2175838T2 (sl) 2017-09-29
PL2175838T3 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
MX2010000315A (es) Un medicamento inhalable.
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
PL2170280T3 (pl) Kompozycja do wdychania zawierająca nikotynę
IL199187A (en) Indole history, pharmaceuticals including them and their use in the manufacture of medicines
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL201101A0 (en) Methods of administering tetrahydrobiopterin associated compositions, and methods of measuring
EP2219616A4 (en) TAXAN DERIVATIVES LYOPHILIZED PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY AND MANUFACTURING METHOD THEREFOR
IL217490A (en) History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
TW200732340A (en) Novel forms of tiotropium bromide and processes for preparation thereof
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2008035380A3 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
IL213590A0 (en) Oxadiazole fused heterocyclic derivatives, their preparation and pharmaceutical compositions containing them
IN2012DN00239A (es)
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2011034514A3 (en) Stable micronized granules having high solubility
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2011156822A3 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration